Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
”Myeloma Paper of the Day:
MAIA final survival analysis shows median OS 90.3 mos w/ DRd vs 64.1 w/ Rd; estimated 7-yr OS rates 53.1% & 39.3%; median TTNT not reached for D-Rd versus 42.4 months for Rd; comparable rate of death due to adverse events.”
Title: Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis
Authors: Thierry Facon, Shaji K. Kumar, Robert Z. Orlowski, Nizar Bahlis, Philippe Moreau, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Weisel, Aurore Perrot, Caroline Jacquet, Noopur Raje, Salomon Manier, Ajai Chari, Markus Hansson, Mohamad Mohty, Michel Delforge, Torben Plesner, Gordon Cook, Xavier Leleu, Hang Quach, Christopher P. Venner, Mourad Tiab, Margaret Macro, Laurent Frenzel, George Wang, Huiling Pei, Kasey Bolyard, Robin Carson, Fredrik Borgsten, and Saad Z. Usmani.
You can read the full article on Leukemia.
You can find other articles featuring Robert Orlowski on OncoDaily.